161 related articles for article (PubMed ID: 9654111)
1. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy.
Grossman SA; Hochberg F; Fisher J; Chen TL; Kim L; Gregory R; Grochow LB; Piantadosi S
Cancer Chemother Pharmacol; 1998; 42(2):118-26. PubMed ID: 9654111
[TBL] [Abstract][Full Text] [Related]
2. Lack of efficacy of 9-aminocamptothecin in adults with newly diagnosed glioblastoma multiforme and recurrent high-grade astrocytoma. NABTT CNS Consortium.
Hochberg F; Grossman SA; Mikkelsen T; Glantz M; Fisher JD; Piantadosi S
Neuro Oncol; 2000 Jan; 2(1):29-33. PubMed ID: 11302251
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
4. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium.
Fetell MR; Grossman SA; Fisher JD; Erlanger B; Rowinsky E; Stockel J; Piantadosi S
J Clin Oncol; 1997 Sep; 15(9):3121-8. PubMed ID: 9294475
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.
Dahut W; Harold N; Takimoto C; Allegra C; Chen A; Hamilton JM; Arbuck S; Sorensen M; Grollman F; Nakashima H; Lieberman R; Liang M; Corse W; Grem J
J Clin Oncol; 1996 Apr; 14(4):1236-44. PubMed ID: 8648379
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.
Minami H; Lad TE; Nicholas MK; Vokes EE; Ratain MJ
Clin Cancer Res; 1999 Jun; 5(6):1325-30. PubMed ID: 10389915
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study.
Langevin AM; Casto DT; Thomas PJ; Weitman SD; Kretschmar C; Grier H; Pratt C; Dubowy R; Bernstein M; Blaney S; Vietti T
J Clin Oncol; 1998 Jul; 16(7):2494-9. PubMed ID: 9667269
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion.
Leguizamo J; Quinn M; Takimoto CH; Liang MD; Ismail AS; Pang J; Dahut W; Grem JL
Cancer Chemother Pharmacol; 2003 Oct; 52(4):333-8. PubMed ID: 12819941
[TBL] [Abstract][Full Text] [Related]
9. Practical implementation of a modified continual reassessment method for dose-finding trials.
Piantadosi S; Fisher JD; Grossman S
Cancer Chemother Pharmacol; 1998; 41(6):429-36. PubMed ID: 9554585
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
Vey N; Kantarjian H; Tran H; Beran M; O'Brien S; Bivins C; Giles F; Cortes J; Cheson B; Arbuck S; Estey E
Ann Oncol; 1999 May; 10(5):577-83. PubMed ID: 10416008
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma.
Pazdur R; Diaz-Canton E; Ballard WP; Bradof JE; Graham S; Arbuck SG; Abbruzzese JL; Winn R
J Clin Oncol; 1997 Aug; 15(8):2905-9. PubMed ID: 9256134
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of topotecan for pediatric central nervous system tumors.
Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.
Chang SM; Kuhn JG; Rizzo J; Robins HI; Schold SC; Spence AM; Berger MS; Mehta MP; Bozik ME; Pollack I; Gilbert M; Fulton D; Rankin C; Malec M; Prados MD
J Clin Oncol; 1998 Jun; 16(6):2188-94. PubMed ID: 9626220
[TBL] [Abstract][Full Text] [Related]
16. Pre-irradiation 9-amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme.
Farray D; Ahluwalia MS; Snyder J; Barnett GH; Cohen BH; Suh JH; Peereboom DM
Invest New Drugs; 2006 May; 24(3):177-80. PubMed ID: 16086097
[TBL] [Abstract][Full Text] [Related]
17. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.
Siu LL; Oza AM; Eisenhauer EA; Firby PS; Thiessen JJ; Michael M; Wainman N; Manzo J; Feld R; Goldberg RA; Moore MJ
J Clin Oncol; 1998 Mar; 16(3):1122-30. PubMed ID: 9508199
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.
Grossman SA; Carson KA; Phuphanich S; Batchelor T; Peereboom D; Nabors LB; Lesser G; Hausheer F; Supko JG;
Neuro Oncol; 2008 Aug; 10(4):608-16. PubMed ID: 18577560
[TBL] [Abstract][Full Text] [Related]
20. Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas.
Wilson WH; Little R; Pearson D; Jaffe ES; Steinberg SM; Cheson BD; Humphrey R; Kohler DR; Elwood P
J Clin Oncol; 1998 Jul; 16(7):2345-51. PubMed ID: 9667249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]